The Silicon Valley-based ShareRoot (ASX:SRO) Medi Consent platform is also designed to improve patient engagement in and around clinical trials and understanding of patients’ health-related behaviour through the use of social media and the proper accompanying consent processes.
Under the collaboration, St Vincents' is working with MediaConsent to offer the first solution within its respective industry to ensure compliance with human research ethics committees, while enhancing the relationship development between the hospital and its patients.
The collaboration, led by Michelle Gallaher, managing director of The Social Science, a Melbourne-based digital agency acquired by ShareRoot in April, includes a group of specialist advisers representing St Vincent’s Hospital’s Research Directorate who ShareRoot says have invaluable knowledge and networks within the global clinical research and clinical trials industry.
The three companies say the growing interest in real world data and real world evidence in the pharmaceutical and medical technology industry by regulators and technology developers worldwide is remarkable – and RWD can be derived, for example, from a number of sources such as wearable technologies and social media.
“Valuable health-related data and content is shared online every day by millions of people via social media,” said ShareRoot chief executive Noah Abelson-Gertler.
“That is where MediaConsent comes into play: our goal is for MediaConsent to be a reliable, sensitive, and ethical platform that reduces the barriers and encourages doctors, nurses and allied health professionals to engage in clinical research with a far wider scope while ensuring that patients and their carers are in control of their data.”